The aesthetic outcome of injections with the Aquamid hydrogel showed that 96% of the 116 patients evaluated after five years had ‘very good’ or ‘good’ aesthetic results according to the physician investigators and 92% of the patients were ‘very satisfied’ or ‘satisfied’. The safety data in the trial showed that injection of Aquamid over a period of five years was safe with few and no unexpected adverse events. The five-year results are consistent with the data from the one-year, two-year and three- to four-year follow-up visits.
Michael Peytz, CEO of Contura, said: “Aquamid is well positioned to meet the global consumer needs for long-lasting aesthetic treatments to restore facial volume. In 2008 we expect to complete the 12-month follow-up in our US clinical trial and look forward to submitting the data to the FDA for review.”